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Abstract
Background
The relationship between dyspnea and incident heart failure (HF) and myocardial infarction
(MI) among patients without previously diagnosed cardiopulmonary disease is unclear. We
studied the prognostic relevance of self-reported dyspnea for cardiovascular outcomes and
all-cause mortality in persons without previously diagnosed cardiopulmonary disease.
Methods and Results
We studied 10 881 community-dwelling participants (mean age 57±6, 56% women, 25%
black) who were free of prevalent cardiopulmonary disease from Atherosclerosis Risk in
Communities Study. Dyspnea status at study entry using the modified Medical Research
Council (mMRC) scale. The primary outcomes were time to HF, MI or all-cause death. Dys-
pnea prevalence was 22%, and was mild (mMRC grade 1 or 2) in 21% and moderate-to-
severe (mMRC 3 or 4) in 1%. The main correlates of dyspnea were older age, female sex,
higher BMI and active smoking. Over a follow-up of 19±5 years, greater self-reported dys-
pnea severity was associated with worse prognosis. Mild dyspnea was associated with sig-
nificantly heightened risk of HF (adjusted Hazard Ratio, HR,1.30; 95% CI: 1.16–1.46), MI
(adjusted HR 1.34; 95%CI: 1.20–1.50), and death (adjusted HR 1.16; 95%CI: 1.06–1.26),
with moderate/severe dyspnea associated with an even greater risk (adjusted HR 2.14,
95%CI: 1.59–2.89; 1.93, 95%CI: 1.41–2.56; 1.96, 95%CI: 1.55–2.48, respectively).
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Conclusion
In community-dwelling persons free of previously diagnosed cardiopulmonary disease,
self-reported dyspnea is common and, even when of mild intensity, it is independently
associated with a greater risk of incident HF, MI, and death. Our data emphasize the prog-
nostic importance of even mild self-reported dyspnea for cardiovascular outcomes.
Introduction
Dyspnea is a subjective experience of breathing discomfort that consists of distinct sensations
of varying intensity[1]. In the general population, the overall prevalence of dyspnea is variable
across studies,[2] related to differences in the distribution of known correlates of dyspnea such
as age, gender, and smoking status, in the burden of comorbidities, and in the instrument used
to measure dyspnea[3]. Despite variable prevalence estimates, dyspnea has been consistently
associatedwith greater mortality in the general population[4, 5]. It is a more powerful predictor
of clinical outcomes than objective physiologic measures such as pulmonary function testing[6,
7] in the general population, or angina in patients referred for cardiac evaluation[8]. However,
little data is available regarding the prognostic relevance of self-reported dyspnea for non-fatal
cardiovascular (CV) outcomes, such as incident myocardial infarction (MI) or heart failure
(HF). In addition, scarce data is available regarding the prevalence and prognostic significance
of dyspnea in African Americans, a population that carries a sizable proportion of the cardio-
vascular disease burden[9, 10].
We determined the prognostic relevance of self-reported dyspnea for CV outcomes in per-
sons without previously diagnosed cardiopulmonary disease.We examined the correlates of
self-reported dyspnea in a large biracial community-based cohort.We then defined the rela-
tionship between the presence and severity of dyspnea and all-cause mortality among partici-
pants with prevalent CV disease (MI, HF, stroke), pulmonary disease (COPD, asthma), or
neither. Finally, among participants without previously diagnosed cardiopulmonary disease,
we determined the prognostic relevance of dyspnea for incident MI and HF.
Methods
Study population
The Atherosclerosis Risk in Communities (ARIC) Study is an ongoing, prospective observa-
tional study. Detailed study rationale, design, and procedures have been previously published
[11]. The original cohort included 15 792 persons aged 45 to 64 years recruited between 1987
and 1989 (Visit 1) from four communities in the United States: Forsyth County, North Caro-
lina; Jackson, Mississippi; Minneapolis, Minnesota; andWashington County, Maryland. Three
subsequent follow-up visits occurred at 3-year intervals, with annual telephone interviews con-
ducted between visits and currently ongoing. The ARIC study has been approved by Institu-
tional ReviewBoards (IRB) at all participating institutions: University of North Carolina at
Chapel Hill IRB, Johns Hopkins University IRB, University of Minnesota IRB, and University
of Mississippi Medical Center IRB. Study participants provided written informed consent at all
study visits.
This analysis was restricted to ARIC participants who attended Visit 2 (1990–1992) and
completed the dyspnea questionnaire (n = 13,425). We restricted our analyses to self-described
black or white participants (40 exclusions due to other race).We analyzed a total of 13 385 U.S.
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adults aged 46 to 70 year-old followed prospectively through 2011 (median follow-up of 19±5
years). From among this population, we identified participants free of prevalent cardiovascular
and pulmonary disease (n = 10 881), defined as the absence of a previous history of HF, MI,
stroke, COPD, and asthma.
Dyspnea Assessment
The modifiedBritish Medical Research Council (mMRC) instrument is an activity-baseddys-
pnea scale that describes five grades of dyspnea according to a positive response to the follow-
ing questions (from the originalMRC questionnaire[12]): dyspnea only with strenuous
exercise (grade 0 or normal); dyspnea when hurrying on level ground or up a slight hill (grade
1); dyspnea when walking at one’s own pace on level ground (grade 2); dyspnea when walking
100 yards or for a fewminutes (grade 3); and dyspnea at rest (grade 4). This questionnaire was
administered to ARIC participants at Visit 2. We further arbitrarily grouped subjects as having
no dyspnea (mMRC grade 0), mild dyspnea (mMRC grade 1 or 2), and moderate to severe dys-
pnea (mMRC grade 3 or 4).
Covariates
Established definitions for hypertension, obesity, diabetes mellitus, HF, coronary heart disease
(CHD), stroke, and smoking status were used as previously described in the ARIC study[13].
Briefly, sitting BP was measured. Recent use of antihypertensive medications, and smoking sta-
tus were self-reported. Fasting plasma total cholesterol and Serumglucose were measured.
Bodymass index (kg/m2) was computed frommeasured weight and height. Preexisting heart
failure was defined as: (1) self report of recent medications for heart failure, or (2) Stage 3 or
“manifest heart failure” by Gothenburg criteria which rest on a physician’s judgment based on
physical exam and history. Preexisting coronary heart disease at baseline was defined by self-
reported prior physician diagnosis, or by evidence of MI by 12-lead ECG. Preexisting stroke
was defined by any self-reported prior physician diagnosis of stroke. Self-reportedCOPD and
asthma were assessed by the answer to the question “Has your doctor ever said you had: 1)
chronic lung disease, such as chronic bronchitis, or emphysema; 2) asthma?”. Physical activity
was expressed as the product of average metabolic equivalents by minutes during a week
(METsmin/week) of moderate-to-vigorous activity. Estimated glomerular filtration rate
(eGFR) was calculated using the CKD Epidemiology Collaboration (CKD-EPI) equation[14].
Medication history was obtained at Visit 2 by self-report of medication use during the previous
two weeks and by reviewingmedications brought by the participants to their visit. All covari-
ates were ascertained at Visit 2 except for physical activity which was ascertained at Visit 1.
Clinical Events
ARIC participants undergo surveillance for incident CHD events (fatal CHD, definite or prob-
able MI, or coronary revascularization) and all-cause mortality as previously described in detail
[15]. Briefly, incident CHD events were defined as the first occurrence of a fatal or non-fatal
MI ascertained through surveillance, abstraction, and physician adjudication of hospitaliza-
tions with CHD-related ICD codes[15] and annual participant contact. Incident HF was based
on HF hospitalization or HF death according to ICD codes (code 410 in any position) obtained
by ARIC surveillanceof hospital discharges[16]. Deaths were ascertainedusing National Death
Index.
Dyspnea and Risk of Cardiovascular Outcomes
PLOS ONE | DOI:10.1371/journal.pone.0165111 October 25, 2016 3 / 15
Statistical analysis
Summary statistics were calculated as counts and percentages for categorical data and means
and standard deviation for continuous data, by dyspnea category. Comparisons of baseline
characteristics between groups were made using Pearson Chi-squared test and analysis of vari-
ance (ANOVA). To determine the cross-sectional correlates of dyspnea, we used linear regres-
sion (mMRC scale as dependent variable) and logistic regression (moderate-to-severe dyspnea
as dependent variable); only covariates with a p<0.05 in univariate analysis were included in
the multivariate model.We determined the rates of mortality, incident HF, and incident MI
per 100 person-years at risk, using the ARIC Visit 2 date as baseline and stratified by dyspnea
category. We usedmultivariable Cox proportional hazards regression models to assess the
unadjusted and adjusted association of dyspnea with mortality, incident HF, incident MI, or
the composite of these. Minimally adjusted models adjusted for age, sex, race, and Center while
fully adjusted models also adjusted for race, hypertension, diabetes, bodymass index (BMI),
current and former smoking status, systolic blood pressure, heart rate, eGFR, hemoglobin, left
ventricular hypertrophy by ECG, statin use, antihypertensive medication use, anticoagulant
use and aspirin use at baseline (Visit 2), as well as physical activity measure at Visit 1[17].
Covariates included in the full multivariable models were selected using a forward stepwise
selection procedure (retention at p<0.05) with all variables that varied significantly between
dyspnea categories (Table 1) included as candidate covariates. The proportional hazards
assumption was assessed by visual inspection of Schoenfeld residuals. We additionally per-
formed subgroup analyses by age, sex, race, and obesity status.
Two-sided p values of<0.05 were considered significant. Analyses were performed using
Stata version 12.1 (Stata Corp., College Station, TX, USA).
Results
Population characteristics
Of the 13 385 participants included in this analysis, the mean age was 57±6 years, 55% were
female, and 25% self-reported black ethnicity. CHD, HF and stroke prevalence were 6%, 4%
and 1.5%, respectively. The prevalence of COPD and asthma were both 5%. The overall preva-
lence of dyspnea was 26%, with mild dyspnea accounting for the majority (23%), and only 3%
reportingmoderate-to-severe dyspnea (Fig 1). Among the 10 881 participants without previ-
ously diagnosedCV or pulmonary disease, dyspnea prevalence was similar at 22% (21% mild,
1% moderate-to-severe; Table 1). Women had a higher prevalence of dyspnea than men (27%
vs 16%, p<0.001). White participants had similar prevalence of dyspnea to black participants
(23% vs 21% respectively; p = 0.09), although the prevalence of moderate-to-severe dyspnea
was greater in blacks than whites (4% vs 1% respectively; p<0.001).
Participants with previously diagnosed cardiopulmonary disease
Prevalent CHD, HF, and COPD were all independently associated with greater odds of any
dyspnea self-report (OR 2.40 [2.04–2.84]; OR 2.74 [2.29–3.28]; OR 4.51 [3.79–5.37], respec-
tively), after multivariable adjustment. They were also independently associated with greater
odds of participant report of moderate-to-severe dyspnea (OR 4.35 [3.15–6.00]; 5.92 [4.51–
7.77]; 9.64 [7.35–12.62], respectively). The presence of any self-reported dyspnea was associ-
ated with heightened risk of dying in participants with prevalent CHD, HF and COPD
(Table 2), with a greater risk in those with moderate-to-severe dyspnea (Fig 2).
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Participants without previously diagnosed cardiopulmonary disease
Correlates of any dyspnea (mMRC>0). Among participants without previously diag-
nosed CV or pulmonary disease, the prevalence of dyspnea was 22% (mild: 21%; moderate-to-
severe: 1%). Demographic characteristics, co-morbidities, LVH, and pulmonary functionwere
Table 1. Baseline characteristics of the studied cohort, by the presence of dyspnea.
Characteristic Overall Non-dyspnea Mild dyspnea Moderate-to-severe dyspnea P-value
(N = 10 881) (n = 8 463) (n = 2 270) (n = 148)
Demographic
Age, y 57±6 56±6 58±6 57±6 <0.001
Male gender, n (%) 4781 (44) 4 014 (47) 728 (32) 39 (26) <0.001
Race, n (%)
White 8 157 (75) 6 312 (75) 1 793 (79) 52 (35) <0.001
Black 2 724 (25) 2 151 (25) 477 (21) 96 (65)
Anthropometric & ECG
BMI, Kg/m2 27.7±5.2 27.3±4.8 29.2±5.9 32.5±7.8 <0.001
SBP, mmHg 121±19 120±18 123±19 129±25 <0.001
DBP, mmHg 72±10 72±10 72±10 75±12 0.002
HR, bpm 65±10 65±10 67±11 68±11 <0.001
LVH, n (%) 240 (2) 169 (2) 55 (2) 16 (11) <0.001
LBBB, n (%) 9 (0) 6 (0) 2 (0) 1 (1) 0.04
Other than Sinus Rhythm, n (%) 31 (0) 22 (0) 9 (1) 0 (0) 0.45
Risk factors & Comorbidities
Hypertension, n (%) 3 602 (33) 2 580 (28) 939 (42) 83 (57) <0.001
Diabetes, n (%) 736 (7) 504 (6) 204 (9) 28 (19) <0.001
Dyslipidemia, n (%) 3 185 (30) 2 352 (28) 784 (35) 49 (34) <0.001
Obesity, n (%) 2 977 (27) 2 014 (24) 875 (39) 88 (60) <0.001
Smoking status
Current, n (%) 2 335 (22) 1 655 (20) 641 (28) 39 (26) <0.001
Former, n (%) 3 995 (37) 3 195 (38) 749 (33) 51 (35) 0.001
Alcohol daily intake, n (%) 3 844 (35) 3 122 (37) 695 (31) 27 (18) <0.001
Alcohol daily intake, g/week 38±93 38±90 37±102 19±58 0.04
Physical Activity, METs*min/week 623±766 672±795 461±630 266±498 <0.001
Blood Analysis and Lung Function
FEV1/FVC, % 77±4 77±4 77±4 73±5 <0.001
FEV1/FVC < 70%, n (%) 1 493 (14) 1 142 (14) 288 (13) 63 (43) <0.001
Hemoglobin, g/dL 13.7±1.3 13.7±1.3 13.6±1.3 13.3±1.5 <0.001
eGFR, mL/min/m2 65±12 65±11 63±12 65±15 <0.001
CKD, n (%) 3 813 (35) 3 333 (34) 927 (41) 53 (36) <0.001
Medication
Anti-hypertensive, n (%) 2 984 (27) 2 120 (25) 789 (35) 75 (51) <0.001
Statin, n (%) 216 (2) 164 (2) 45 (2) 7 (5) 0.05
Anticoagulant, n (%) 31 (0) 18 (0) 12 (1) 1 (1) 0.03
Aspirin, n (%) 5 207 (48) 3 901 (46) 1 233 (55) 73 (50) <0.001
Abbreviations: BMI, body mass index; CKD, chronic kidney disease (eGFR < 60 mL/min/1.73m2); DBP, diastolic blood pressure; ECG, electrocardiogram;
eGFR, estimated glomerular filtration rate; FEV1, forced expiratory volume in the first second; FVC, functional vital capacity; HR, heart rate; LBBB, left
bundle branch block; LVH, left ventricular hypertrophy; MET, metabolic equivalent; SBP, systolic blood pressure.
doi:10.1371/journal.pone.0165111.t001
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all associated with dyspnea self-report (S2 Table). In multivariable analysis, age, sex, race, BMI,
diabetes, hypertension and active smoking status were independent predictors of dyspnea.
Together, the variables associated with dyspnea self-report only explained 7% of the variance
in self-report of any dyspnea in this cohort.
Correlates of moderate-to-severedyspnea (mMRC 3 or 4). Among participants without
previously diagnosedCV and pulmonary disease, the prevalence of moderate-to-severe dys-
pnea was 1%. Cardiovascular risk factors such as BMI and diabetes were significantly associ-
ated with moderate-to-severe dyspnea, while smoking status and FEV1/FVC ratio were not (S2
Table). Female sex was also an independent predictor of moderate-to-severe dyspnea. Similar
to dyspnea in the overall population, these variables together only explained 8% of the variance
in self-report of moderate-to-severe dyspnea.
Prognostic significanceof dyspnea in personswithout prevalent cardiopulmonarydis-
ease:Mortality. Participants were followed from 1990–1992 through December 31, 2011,
Fig 1. Dyspnea prevalence, by prevalence of cardiopulmonary disease, age, gender, race, and
obesity.
doi:10.1371/journal.pone.0165111.g001
Dyspnea and Risk of Cardiovascular Outcomes
PLOS ONE | DOI:10.1371/journal.pone.0165111 October 25, 2016 6 / 15
with a mean of 19±5 years of follow-up. All-cause mortality occurred in 32% (n = 4 240) of the
overall cohort, 2 352 in men and 1 888 in women. Table 2 shows mortality rates according to
the presence of dyspnea among participants with no prevalent CV and pulmonary disease. The
median time to death was 14.7 [9.7–18.4] years. Dyspnea self-report was associated with a sig-
nificant 20% higher risk of dying during the follow-up period (Hazard Ratio, HR, 1.20 [1.10–
1.31]). Bothmild dyspnea (HR 1.16 [1.06–1.26]) and moderate-to-severe dyspnea (HR 1.96
[1.55–2.48]) were independently associated with greater mortality when compared to no dys-
pnea, with a greater risk associated with moderate-to-severe dyspnea than mild dyspnea.
In the overall cohort (including those with and without previously diagnosed cardiopulmo-
nary disease), dyspnea was associated with a 25% increase in the risk of dying (HR-1.25 95%
CI: 1.16–1.34) after adjusting for the presence of cardiopulmonary disease.While dyspnea was
a significant predictor of all-causemortality both among persons with and without prevalent
cardiopulmonary disease, the magnitude of risk associated with dyspnea was greater in those
with previously known cardiopulmonary disease (HR 1.35, 95% CI 1.19–1.54 and HR 1.13,
95% CI 1.04–1.24 among those with and without prevalent cardiopulmonary disease respec-
tively; p-value for interaction:<0.001).
Prognostic significanceof dyspnea in personswithout prevalent cardiopulmonarydis-
ease: Cardiovascularoutcomes. Incident myocardial infarction occurred in 1 128 (10%), and
incident heart failure in 1 578 (15%) participants during follow-up. The median time to HF
and MI were 13.8 [8.8–17.9] and 11.0 [6.3–16.2] years, respectively. Dyspnea was indepen-
dently associated with higher risk of incident HF and of incident MI (Table 2; Fig 3). When
Table 2. Multivariable adjusted hazard ratios for death and incident heart failure and myocardial infarction with dyspnea.
Number of events/ Total at risk Event Rate Per 100 person-years (95% CI) Unadjusted HR (95% CI) Adjusted HR (95% CI)
Men
Incident HF
No dyspnea 571/4 014 0.79 (0.73–0.86) Reference Reference
Any dyspnea 191/767 1.58 (1.37–1.82) 1.89 (1.61–2.23) 1.34 (1.12–1.59)
Incident CHD
No dyspnea 517/4 014 0.72 (0.66–0.79) Reference Reference
Any dyspnea 153/767 1.27 (1.08–1.49) 1.66 (1.38–1.99) 1.29 (1.06–1.57)
Death
No dyspnea 1239/4 014 1.62 (1.53–1.72) Reference Reference
Any dyspnea 382/767 2.89 (2.61–3.20) 1.68 (1.50–1.88) 1.33 (1.17–1.50)
Women
Incident HF
No dyspnea 482/4 014 0.57 (0.52–0.62) Reference Reference
Any dyspnea 334/767 1.12 (1.01–1.26) 1.92 (1.67–2.21) 1.38 (1.19–1.60)
Incident CHD
No dyspnea 292/4 014 0.34 (0.31–0.38) Reference Reference
Any dyspnea 166/767 0.55 (0.47–0.64) 1.55 (1.28–1.88) 1.22 (1.00–1.50)
Death
No dyspnea 917/4 449 1.04 (0.97–1.10) Reference Reference
Any dyspnea 474/1651 1.49 (1.37–1.63) 1.32 (1.18–1.47) 1.10 (0.98–1.24)
Abbreviations: Minimally adjusted HR included in the models the following covariates: age, gender, race and field center. Adjusted HR included in the
models the following covariates: visit center, age, sex, race, hypertension, diabetes, body mass index (BMI), current and former smoking status, systolic
blood pressure, heart rate, eGFR, hemoglobin, left ventricular hypertrophy, statin use, antihypertensive medication use, anticoagulant use and aspirin use
at baseline and physical activity.
doi:10.1371/journal.pone.0165111.t002
Dyspnea and Risk of Cardiovascular Outcomes
PLOS ONE | DOI:10.1371/journal.pone.0165111 October 25, 2016 7 / 15
Fig 2. Mortality according to dyspnea severity among patients with (A) prevalent heart failure
(n = 575), (B) prevalent coronary heart disease (N = 721), and (C) prevalent chronic obstructive
pulmonary disease (n = 630).
doi:10.1371/journal.pone.0165111.g002
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Fig 3. Survival curves of patients with no prevalent CV or pulmonary disease according to dyspnea
status regarding death, incident HF and MI.
doi:10.1371/journal.pone.0165111.g003
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compared to participants reporting no dyspnea, both mild dyspnea and moderate-to-severe
dyspnea were each independently associated with a heightened risk of incident HF and of
incident MI, with moderate-to-severe dyspnea conveying a greater risk than mild dyspnea
(Table 2).
Subgroup analyses among participants without prevalence CV or
pulmonary disease
Women. The prevalence of both mild dyspnea and moderate-to-severe dyspnea was
greater in women compared to men (25% vs 15%, p<0.001; 1.8% vs 0.8%, p<0.001, respec-
tively). Men had higher mortality rate than women, and the risk of death associated with dys-
pnea self-report was also higher in men than women (hazard ratio: 1.33 [95% CI: 1.17–1.50] vs
1.10 [95% CI: 0.98–1.24]; p-value for interaction = 0.008; S3 Table). The risk of incident HF
and incident MI associated with dyspnea self-report was similar among women compared to
men, with no significant interaction between dyspnea self-report and sex for either of these
outcomes.
Race. Blacks had a higher prevalence of cardiovascular comorbidities including hyperten-
sion, diabetes, obesity, and active smoking status than whites. Among both black and white
participants, the presence of dyspnea was associated with a higher risk of incident HF, MI, and
death compared to those with no dyspnea, without evidence of significant interaction between
race and dyspnea (interaction p = 0.72, 0.31, 0.14 respectively; S4 Table). Of note, while the rel-
ative risk associated with dyspnea was similar between races, absolute mortality rates in blacks
were significantly higher than in whites (1.20 vs 1.63 per 100-person-years), as were incident
HF and MI rates (S4 Table), resulting in a greater increase in absolute event rate associated
with dyspnea self-report in blacks.
Obesity. BMI was associated with a higher prevalence of dyspnea: Forty-one percent of
participants with a BMI> 30 Kg/m2 reported dyspnea, compared to 20% of those with a BMI
between 25–30 Kg/m2 (p<0.001). Among both obese and non-obese participants, self-reported
dyspnea was associated with a heightened risk of outcomes without significant interaction
between BMI and dyspnea in relation to risk of HF (p = 0.41), risk of MI (p = 0.14) and mortal-
ity (p = 0.52; S5 Table).
Age. Age was associated with a higher prevalence of dyspnea: 20% of participants in the
lowest age quartile (mean age of 49 years) compared with 33% of participants in highest quar-
tile (mean age of 65 years). No significant interaction between dyspnea self-report and age was
found for incident HF (p = 0.65), or death (p = 0.51; S6 Table). The risk of incident MI was
higher in older (>56 years; mean age: 62±3 years) compared to younger (<56 years; mean age:
52±3 years) participants (HR 1.04, 95% CI: 0.80–1.36 vs HR 1.34, 95% CI: 1.14–1.59, respec-
tively; p for interaction = 0.007; S6 Table).
Discussion
In this prospective study of over 13 000 adults from a community-based, biracial cohort, we
observed an overall dyspnea prevalence of 26%. Older age, female sex, obesity, and active
smoking status were the main correlates of dyspnea. Regardless of dyspnea severity or the pres-
ence of prevalent cardiopulmonary disease, self-report of dyspnea at study entry predicted
death and non-fatal cardiovascular events. Notably, mild dyspnea in participants with no pre-
vious diagnosis of cardiopulmonary disease was consistently associated with a higher risk of
incident HF, MI, and death. Despite being related to dyspnea, accounting for age, sex, race and
obesity did not appreciably attenuate its overall prognostic significance.
Dyspnea and Risk of Cardiovascular Outcomes
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A dyspnea prevalence of 26% in our middle-aged cohort is consistent with previous popula-
tion-based reports[2] [4, 18]. Gronseth et al.[2] also used the mMRC scale to measure dyspnea
in over 9000 subjects around the world and found an overall dyspnea prevalence of 27%. In the
subset of US participants (416 subjects) the prevalence was much higher (47%), mainly due to
self-reportedmild dyspnea. The higher prevalence of obesity and heart disease in US subjects
recruited into that study may contribute to the observeddifferences to our study. Importantly,
in the ARIC cohort, the prevalence of self-reported dyspnea did not change much (26% to
22%) after excluding participants with a previous history of cardiovascular (CHD, HF, stroke)
or pulmonary (COPD, asthma) disease. Consistent with previous studies [2, 19, 20], we found
several correlates of dyspnea such as age, gender and obesity. Together these only explained 8%
of the variance in dyspnea self-report. This may reflect unmeasured variables (e.g. cardiovascu-
lar function,musculoskeletal abnormalities) possibly causing dyspnea, individual and cultural
differences in the recognition and expression of dyspnea, and limitations of the mMRC dys-
pnea measurement scale. This scale only measures the functional burden of dyspnea and does
not capture other important dimensions like the sensorial and affective dimensions assessed by
other measurement tools[1].
Dyspnea was an independent predictor of all-causemortality. This association was observed
for both mild and moderate-to-severe dyspnea, as well as for participants with and without his-
tory of cardiorespiratory diseases (COPD, asthma, HF, CHD, and stroke). Age, gender, and
obesity correlated with self-reported dyspnea and, despite the mechanistic explanations that
may link these features with dyspnea, they did not modify the prognostic impact of dyspnea on
mortality and cardiovascular outcomes. Our finding that self-reported dyspnea predicts mor-
tality is consistent with previous population-based studies looking both at healthy and diseased
subjects[4, 8]. However, we extend existing knowledge on the prognostic value of dyspnea by
demonstrating that—among participants with no previously diagnosed cardiovascular and
respiratory disease—self-reported dyspnea is associated with a higher risk of developing HF or
MI.With respect to magnitude of effect, a gradient of risk was noted frommild to moderate-
to-severe dyspnea for incident HF, MI, and death.
There are several potential explanations for the observedassociation between self-reported
dyspnea and non-fatal cardiovascular outcomes in participants without previously diagnosed
disease. Although we had focused on participants without prevalent cardiopulmonary diseases,
we cannot exclude the possibility of dyspnea being an expression of undiagnosed cardiovascular
disease, even though the time lag between self-reported dyspnea and events (median of 11 to
13.8 years) may argue against it. Dyspneamay also be a surrogate marker of physical decondi-
tioning due to low physical activity levels, which has been independently associatedwith cardio-
vascular outcomes[21]. Despite the adjustments for physical activity levels measured 2 years
before dyspnea assessment, we cannot rule-out physical activity as a residual confounder or,
alternatively, a mechanism through which dyspnea increase the risk of cardiovascular events.
Finally, dyspnea may signal greater overall frailty, characterized by excess vulnerability to envi-
ronmental stressors and reduced ability to maintain homeostasis after a destabilizing event[22].
Our data does not inform the causes and mechanisms behind dyspnea. Indeed traditional
cardiac and pulmonary risk factors explained only a small amount of the variability in dyspnea
self-report.However, this analysis clearly demonstrates that dyspnea is a common symptom in
the general population, and—perhaps more importantly—an independent risk factor for
adverse outcomes including incident HF and MI, and death. This holds true for middle-aged
or elderly, women and men, and blacks or whites. Importantly, self-reported dyspnea (mild or
moderate-to-severe)was also of similar prognostic value among obese or non-obese persons
free of previously diagnosed cardiopulmonary disease. The 21% increase in risk of incident MI
associated with dyspnea was significant, but more modest than other established coronary
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disease risk factors such a active smoking which was associated with 97% increase in risk in our
study sample. Similarly, the significant 28% increase in risk for incident HF associated with
dyspnea is more modest than the 55% increase in risk associated with obesity (defined as a
BMI> 30Kg/m2; S7 Table). These consistent data stress the clinical importance of patient
reported dyspnea, and emphasize the prognostic information that this subjective symptom
conveys even in those patients with lower functional capacity, such as the elderly and obese.
Further research is necessary to evaluate the mechanisms linking self-reported dyspnea to car-
diovascular outcomes or the utility diagnostic testing to mitigate this risk. However, our find-
ings suggest that providers should have a high index of suspicion for underlying cardiovascular
—in addition to pulmonary—diseasewhen confronted with patients reporting dyspnea, even
in the context of advanced age or obesity.
Several limitations of our analysis should be considered. Given the observational nature of
our study, we cannot rule-out potential confounding by unmeasured factors as contributors
to the observed associations between dyspnea and cardiovascular outcomes. No echocardio-
graphic data was available, therefore we cannot exclude the presence of undiagnosed structural
heart disease (e.g. valvular heart disease).We used a single measurement of dyspnea, and there-
fore we cannot account for the influence of duration and variation in symptom reporting over
time on the risk of developing cardiovascular events. Our variable of interest was a symptom
that is commonly present in patients with HF and CHD. This could favor a detection bias if an
uneven probability of undergoing diagnostic procedures occurred between participants report-
ing versus not reporting dyspnea. The consistent results regarding mortality, and the ascertain-
ment of nonfatal cardiovascular outcomes using hospitalization, make this potential bias less
important. The restricted number of blacks in the ARIC study increase the probability of a type
II error as power was limited for examining race differences in the association between dyspnea
and cardiovascular outcomes, although this remains a sizeable sample of black participants for
an epidemiologic cohort study.
Conclusions
Dyspnea is a prevalent symptom among middle-aged persons free of previously diagnosed car-
diovascular disease and is independently associated with a heightened risk of developing heart
failure, myocardial infarction and death. Regardless the underlyingmechanism, dyspnea signals
a worse clinical course independent of subject characteristics such as age, sex, race, or BMI.
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